Chemical Component Summary | |
---|---|
Name | Bedaquiline |
Identifiers | (1R,2S)-1-(6-bromanyl-2-methoxy-quinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenyl-butan-2-ol |
Formula | C32 H31 Br N2 O2 |
Molecular Weight | 555.505 |
Type | NON-POLYMER |
Isomeric SMILES | CN(C)CC[C@@](c1cccc2c1cccc2)([C@H](c3ccccc3)c4cc5cc(ccc5nc4OC)Br)O |
InChI | InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3/t30-,32-/m1/s1 |
InChIKey | QUIJNHUBAXPXFS-XLJNKUFUSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 68 |
Chiral Atom Count | 2 |
Bond Count | 72 |
Aromatic Bond Count | 28 |
Drug Info: DrugBank
DrugBank ID | DB08903 |
---|---|
Name | Bedaquiline |
Groups | approved |
Description | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity.[A261866] Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP.[A261866] Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB).[L48506] Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome.[A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market.[A261856] Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] |
Synonyms |
|
Brand Names | Sirturo |
Indication | Bedaquiline is indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.[L48506] This indication is approved under FDA accelerated approval based on time to sputum culture conversion. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.[L48506] |
Categories |
|
ATC-Code | J04AK05 |
CAS number | 843663-66-1 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
ATP synthase subunit c | MDPTIAAGALIGGGLIMAGGAIGAGIGDGVAGNALISGVARQPEAQGRLF... | unknown | inhibitor |
Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | substrate |
Serum albumin | MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA... | unknown | binder |
Alpha-1-acid glycoprotein 1 | MALSWVLTVLSLLPLLEAQIPLCANLVPVPITNATLDQITGKWFYIASAF... | unknown | binder |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL376488 |
PubChem | 5388906 |
ChEMBL | CHEMBL376488 |
ChEBI | CHEBI:72292 |
CCDC/CSD | KIDWAW, KIDWAW01 |
COD | 2022265 |